We have recently looked a B2microbgolulin which we believe is an important prognostic marker in patients with mismatch repair deficient colorectal cancer.
Poor prognosis was prognosed with the presence of KRAS mutation and RASSF2A methylation in patient serum, and 79% of these patients had progressive disease at 6 months compared with only 9% of patients without the markers. After 1 year, only 14% of patients with mutant DNA in their serum had no signs of disease progression compared with 73% of patients with mutant DNA in their tumor.